# Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

> **NCT04539327** · — · COMPLETED · sponsor: **Grupo Español de Investigación en Cáncer de Ovario** · enrollment: 51 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT04539327
- **Lead sponsor:** Grupo Español de Investigación en Cáncer de Ovario
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539327, "Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04539327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*